Few biopharmaceutical companies have announced $100m-plus venture capital mega-rounds so far this year and the ability to raise cash in 2023 generally has been described as muted relative to the record-breaking years of 2021 and 2022. But a new source of funding has emerged with a very large pot of cash – Patient Square Capital’s inaugural $3.9bn private equity fund – and based on the firm’s history of investments, mega-rounds may be back on the table for some drug developers this year.
Patient Square Equity Partners, as the fund is known, exceeded Patient Square Capital’s $3bn fundraising goal, the firm said on...
Welcome to Scrip
Create an account to read this article
Already a subscriber?
